Artiva Biotherapeutics, Inc. (NASDAQ: ARTV)

Sector: Healthcare Industry: Biotechnology CIK: 0001817241
P/B 1.64
P/E -2.68
P/S 0.00
Market Cap 212.46 Mn
ROIC (Qtr) -56.83
Div Yield % 0.00
Rev 1y % (Qtr) 0.00
Total Debt (Qtr) 11.69 Mn
Debt/Equity (Qtr) 0.09

About

Stock Price Chart

Analysis

Pros

  • Healthy cash reserves of 25.97M provide 8.19x coverage of short-term debt 3.17M, demonstrating strong liquidity position and minimal refinancing risk.
  • Strong tangible asset base of 148.86M provides 12.73x coverage of total debt 11.69M, indicating robust asset backing and low credit risk.
  • Short-term investments of 97.46M provide solid 13.73x coverage of other current liabilities 7.10M, indicating strong liquidity.
  • Tangible assets of 148.86M provide robust 20.97x coverage of other current liabilities 7.10M, indicating strong asset backing.
  • Cash reserves of 25.97M provide robust 2.34x coverage of current liabilities 11.12M, indicating strong short-term solvency.

Cons

  • Operating cash flow of (76.67M) barely covers its investment activities of 46.41M, with a coverage ratio of -1.65, indicating heavy reliance on external financing for growth which may not be sustainable in a tighter credit environment.
  • Investment activities of 46.41M provide weak support for R&D spending of 65.86M, which is 0.70x, suggesting potentially insufficient investment in innovation relative to other capital deployment.
  • Short-term investments of 97.46M significantly exceed cash reserves of 25.97M, which is 3.75x, indicating potentially excessive yield-seeking behavior at the expense of liquidity.
  • The company's operating cash flow of (76.67M) shows concerning coverage of stock compensation expenses of 7.42M, with a -10.34 ratio indicating potential earnings quality issues.
  • Free cash flow of (78.91M) provides weak coverage of capital expenditures of 2.23M, with a -35.38 ratio suggesting additional external financing needs for growth initiatives.

Peer Comparison

Companies in the Biotechnology
S.No. Ticker Company Market Cap P/E P/S Total Debt (Qtr)
1 SMMT Summit Therapeutics Inc. 1,349.40 Bn -1,464.17 0.00 0.01 Bn
2 ONC BeOne Medicines Ltd. 437.43 Bn 6,381.20 87.97 1.90 Bn
3 VRTX Vertex Pharmaceuticals Inc / Ma 116.09 Bn 31.59 9.90 1.83 Bn
4 REGN Regeneron Pharmaceuticals, Inc. 78.10 Bn 17.06 5.48 2.71 Bn
5 ALNY Alnylam Pharmaceuticals, Inc. 55.87 Bn 1,282.42 17.40 3.21 Bn
6 ARGX Argenx Se 52.85 Bn 35.08 27,559.65 -
7 BNTC Benitec Biopharma Inc. 41.75 Bn -998.33 0.00 0.00 Bn
8 INSM INSMED Inc 37.80 Bn -31.93 84.56 0.74 Bn

Industry Comparisons

Current Valuation

Metric Value Industry Percentile
EV to Assets 1.32 12.31
EV to Cash from Ops. -2.57 23.25
EV to Debt 16.83 738.44
EV to EBIT -2.48 -9.16
EV to EBITDA -2.35 6.95
EV to Free Cash Flow [EV/FCF] -2.49 21.90
EV to Market Cap 0.93 65.67
EV to Revenue 0.00 227.32
Price to Book Value [P/B] 1.64 22.34
Price to Earnings [P/E] -2.68 -11.77

Dividend Metrics

Metric Value Industry Percentile
Dividend Coverage Ratio 0.00 -11.94
Dividend Payout Ratio % 0.00 0.16
Dividend per Basic Share 0.00 0.01
FCF Dividend Payout Ratio % 0.00 -0.14
Interest Coverage 0.00 841.00

Growth Metrics

Metric Value Industry Percentile
Capex Growth (1y) % -83.69 -27.13
Cash and Equivalents Growth (1y) % -53.74 734.65
Dividend Growth (1y) % 0.00 0.01
EBIAT Growth (1y) % -29.23 -46.93
EBITDA Growth (1y) % -42.72 -1.68
EBIT Growth (1y) % -29.38 -56.45
EBT Growth (1y) % -29.38 -12.70
EPS Growth (1y) % 97.77 -28.31
FCF Growth (1y) % -50.95 -31.90
Gross Profit Growth (1y) % 0.00 226.84

Liquidity Ratios

Metric Value Industry Percentile
Asset Utilization Ratio 0.00 0.14
Cash Payout Ratio 0.00 0.00
Cash Ratio 2.34 3.85
Current Ratio 11.65 7.27
Debt to Equity Ratio 0.09 0.40
Interest Cover Ratio 0.00 841.00
Times Interest Earned 0.00 841.00

Profitability

Metric Value Industry Percentile
EBITDA Margin % 0.00 -18,234.31
EBIT Margin % 0.00 -18,580.80
EBT Margin % 0.00 -19,488.74
Gross Margin % 0.00 -7.59
Net Profit Margin % 0.00 -19,439.22